| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000023361 |
| Receipt No. | R000026612 |
| Scientific Title | A Phase II Study of Short-course Radiotherapy Preoperatively followed by Capecitabine and Oxaliplatin (XELOX) for cT3 Node-positive Lower Rectal Cancer |
| Date of disclosure of the study information | 2016/08/01 |
| Last modified on | 2020/07/31 (Ver. 5) |
| Basic information | ||
| Public title | A Phase II Study of Short-course Radiotherapy Preoperatively followed by Capecitabine and Oxaliplatin (XELOX) for cT3 Node-positive Lower Rectal Cancer | |
| Acronym | ADVANCE-RC study | |
| Scientific Title | A Phase II Study of Short-course Radiotherapy Preoperatively followed by Capecitabine and Oxaliplatin (XELOX) for cT3 Node-positive Lower Rectal Cancer | |
| Scientific Title:Acronym | ADVANCE-RC study | |
| Region |
|
|
| Condition | ||||
| Condition | Low rectal cancer | |||
| Classification by specialty |
|
|||
| Classification by malignancy | Malignancy | |||
| Genomic information | NO | |||
| Objectives | |
| Narrative objectives1 | To evaluate the safety and efficacy of neoadjuvant short-course radiotherapy followed by XELOX for cT3N1 low rectal cancer at high risk of local and distant recurrence. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | R0 resection rate |
| Key secondary outcomes | Safety (incidence of adverse events), Pathological complete response (pCR), Down-staging rate, Disease-free survival (DFS), local recurrence rate |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Preoperative short-course radiotherapy (5x5 Gy)
XELOX+BEV (4 courses) as neoadjuvant setting. Capecitabine: 2000mg/m2 d1-14 Oxaliplatin: 130mg/m2 d1 Q3w |
|
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1. Histological confirmation of adenocarcinoma.
2. The inferoior border of the tumor below the peritoneal reflection. 3. No distant metastases. 4. No lateral lymph node metastases. 5. Pelvic MRI shows i) cT3, ii) cN1 or extramural vascular invasion (EMVI+), and iii) circumferential resection margin (CRM) >1mm 6. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1. 7. No previous preoperative radiotherapy or chemotherapy for rectal cancer. 8. Age: 20- years old. 9. Written informed consent. 10. Vital organ functions (listed below) are preserved within 2 weeks prior to entry. i. Neutrophils>or=1500/mm3 ii. Platelets>or=100,000/mm3 iii. Hemoglobin>or=9.0g/dl iv. AST, ALT and ALP =or<upper limit of normal (ULN)*2.5 v. Total bilirubin =or<upper limit of normal (ULN)*1.5 vi. Serum creatinine =or<upper limit of normal (ULN)*1.5 11. If there is bowel obstruction or strong stricture, stoma construction before preoperative therapy. |
|||
| Key exclusion criteria | 1. cT4 or cN2.
2. CRM less than 1mm. 3. Administration contraindication of oxaliplatin or capecitabine. 4. History of the serious hypersensitivity for any agents. 5. History of pelvic irradiation. 6. Uncontrolled active infection. 7. Clinically significant complication (heart failure, interstitial lung disease or pulmonary fibrosis, uncontrolled diabetes, renal failure, liver failure, etc.) 8. Evidence of peripheral sensory neuropathy. 9. Uncontrolled diarrhea. 10. Uncontrolled pleural effusion or ascites. 11. Multiple primary cancer within 5 years. 12. Possible pregnant, pregnant or breast-feeding female. 13. Other conditions not suitable for this study. |
|||
| Target sample size | 36 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Cancer Institute Hospital of Japanese Foundation for Cancer Research | ||||||
| Division name | Gastroenterological Surgery | ||||||
| Zip code | 135-8550 | ||||||
| Address | 3-8-31, Ariake, Koto-ku, Tokyo | ||||||
| TEL | +81-3-3520-0111 | ||||||
| takashi.akiyoshi@jfcr.or.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Cancer Institute Hospital of Japanese Foundation for Cancer Research | ||||||
| Division name | Gastroenterological Surgery | ||||||
| Zip code | 135-8550 | ||||||
| Address | 3-8-31, Ariake, Koto-ku, Tokyo | ||||||
| TEL | +81-3-3520-0111 | ||||||
| Homepage URL | |||||||
| takashi.akiyoshi@jfcr.or.jp | |||||||
| Sponsor | |
| Institute | Cancer Institute Hospital of Japanese Foundation for Cancer Research |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Cancer Institute Hospital of Japanese Foundation for Cancer Research |
| Organization | |
| Division | |
| Category of Funding Organization | Other |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Cancer Institute Hospital of Japanese Foundation for Cancer Research |
| Address | 3-8-31, Ariake, Koto-ku, Tokyo |
| Tel | +81-3-3520-0111 |
| s.takahashi-chemotherapy@jfcr.or.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | 28 |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000026612 |